Adaptive Biotechnologies Corporation
HealthcareNASDAQ:ADPT · NASDAQ Global Select
-$1.13 today
Vol 2.96M · Avg 1.96M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-27.2%
avg -27.9%
ROIC
-13.1%
avg -21.5%
ROA
-11.6%
avg -18.6%
Analysis
ROA is currently the strongest return metric at -11.6% versus its period average of -18.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Chad Robins | Co-Founder, Chief Executive Officer & Chairman | $1.41M | — | 51 | $1.51M | 0.94% |
Harlan S. Robins | Co-Founder & Chief Scientific Officer | $834,475.00 | — | 53 | $1.51M | 0.94% |
Julie Rubinstein | President & Chief Operating Officer | $820,495.00 | — | 54 | $377,802.00 | 0.24% |
Sharon Benzeno | Chief Commercial Officer of Immune Medicine | $720,401.00 | — | 52 | $272,751.00 | 0.17% |
Susan Bobulsky | Chief Commercial Officer of MRD | $666,243.00 | — | 45 | $416,775.00 | 0.26% |
Kyle Piskel | Vice President, Chief Financial Officer & Principal Accounting Officer | $608,229.00 | — | 42 | $256,725.00 | 0.16% |
Christopher Carlson | Founder | — | — | — | — | — |
Clarice McCauley | Head of Legal, Corporate Secretary, VP & Chief Compliance Officer | — | — | — | — | — |
Karina Calzadilla | Vice President of Investor Relations | — | — | — | — | — |
Mary Pat Lancelotta | Senior Vice President of MRD BioPharma | — | — | — | — | — |
Francis T. Lo | Chief People Officer | — | — | 45 | $278,955.00 | 0.17% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
74
$43.73M
Net Sentiment
$43.73M
Net selling
Most Active
RUBINSTEIN JULIE
47 transactions
1–10 of 74
Analysis
Insiders reported 0 buys worth $0.00 and 74 sells worth $43.73M over the last 12 months. That adds up to net selling of $43.73M. RUBINSTEIN JULIE was the most active insider with 47 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +40.5% | +17.5% (9yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +40.5% over three years. Forward estimates point to Revenue at +17.5% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.63B
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.67B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Who manages ADPT?
Adaptive Biotechnologies Corporation (ADPT) lists 11 active executives. The top listed executive is Harlan S. Robins, Co-Founder & Chief Scientific Officer.
Are ADPT insiders buying or selling?
Recent insider activity shows net selling of $42.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.